Poulikakos, Poulikos I.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,454

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,163

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 562

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 543

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 442

New perspectives for targeting RAF kinase in human cancer

Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 404

SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors

Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 214

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 179

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

Xiong, Y., Zhong, Y., Yim, H., Yang, X., Park, K.-S., Xie, L., Poulikakos, P. I., Han, X., Xiong, Y., Chen, X., et al. (2022) · Journal of the American Chemical Society

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 154

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 145

Resistance to MEK inhibitors: should we co-target upstream?

Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 119

BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology

Bigenwald, C., Le Berichel, J., Wilk, C. M., Chakraborty, R., Chen, S. T., Tabachnikova, A., Mancusi, R., Abhyankar, H., Casanova-Acebes, M., Laface, I., et al. (2021) · Nature Medicine

Histiocytic Disorders and TreatmentsTelomeres, Telomerase, and Senescence

Cited by 83